By using modern supercomputers and machine learning systems to predict how molecules will act, drugmakers can quickly identify plausible drug candidates, saving both time and money.
Merck, Sanofi and Johnson and Johnson are among the major pharmaceutical giants partnering with technology firms to bring AI to the drug discovery process. GlaxoSmithKline represents the most recent drugmaker to join the bandwagon, agreeing to a $43 million deal with the Scotland-based technology company Exscientia on June 2.
“Many large pharma companies are starting to realize the potential of this approach and how it can help improve efficiencies,” Exscientia CEO Andrew Hopkins told Reuters.
Mr. Hopkins, a former Pfizer employee, said his company’s AI technology could choose ideal drug candidates in about one-fourth the time and for one-fourth the cost of traditional methods.
More articles on supply chain:
Talc powder shortage complicates lung disease treatment for hospitals
4 FDA decisions to look for in July
Red Cross, Children’s Hospital LA face critical blood shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
